异基因治疗剂将选定的标准氟达拉滨和环磷胺作为嗜氧磷去除方案，用于评估西玛卡布烯Ansegedleucel在一线巩固治疗大B细胞淋巴瘤中的作用

2025-08-01 20:37

Lymphodepletion Regimen Selection Made in Conjunction with the ALPHA3 Data and Safety Monitoring Board (DSMB) and Steering Committee, and in Consultation with the FDA Following an ALLO-647-Related Death in the FCA (FC plus ALLO-647) Lymphodepletion Arm
Unplanned Review of Safety and Biomarker Data with Standard FC and Cema-cel Indicates Encouraging MRD Conversion Rate and Safety Profile
ALPHA3 Study Now Proceeds as a Two-Arm Randomized Study Comparing Cema-cel After Standard FC Lymphodepletion to Observation; Scheduled Futility Analysis Remains 1H 2026, as Planned
Conference Call and Webcast Scheduled for Today at 8:00 AM PT/11:00 AM ET